Uncertainty‐conscious methodology for process performance assessment in biopharmaceutical drug product manufacturing

Abstract

This work presents an uncertainty‐conscious methodology for the assessment of process performance—for example, run time—in the manufacturing of biopharmaceutical drug products. The methodology is presented as an activity model using the type 0 integrated definition (IDEF0) functional modeling method, which systematically interconnects information, tools, and activities. In executing the methodology, a hybrid stochastic–deterministic model that can reflect operational uncertainty in the assessment result is developed using Monte Carlo simulation. This model is used in a stochastic global sensitivity analysis to identify tasks that had large impacts on process performance under the existing operational uncertainty. Other factors are considered, such as the feasibility of process modification based on Good Manufacturing Practice, and tasks to be improved is identified as the overall output. In a case study on cleaning and sterilization processes, suggestions were produced that could reduce the mean total run time of the processes by up to 40%. © 2017 American Institute of Chemical Engineers AIChE J, 64: 1272–1284, 2018

Challenges in Optimization and Control of Biobased Process Systems: An Industrial-Academic Perspective

“…In general, cycle times and cleaning routines can and should be analyzed and optimized based on statistical evidence in process data. 166,167 An interesting trade-off between capacity and costs or environmental impact can arise, which is, for instance, discussed in an optimal scheduling context in ref 168.…”

Superstructure-based process synthesis and economic assessment under uncertainty for solid drug product manufacturing

“…In addition, the same amount of placebo is produced for the main and low doses in proportional dosage. For the low dose in common dosage, additional production of placebo is not required because the tablet size is the same as the main dose from the distributions before and after changing the critical parameter [43].…”

Show Me the Money! Process Modeling in Pharma from the Investor’s Point of View

“…This line of thought has been perpetuating though some recent efforts that hint that blending science-based solutions with engineering approaches is growing momentum [7]. Moreover, and perhaps more importantly, there is a growing volume of research efforts (i) corroborating both the pertinence and the efficacy of M&S on both upstream and downstream [8][9][10], (ii) offering holistic and industrial-friendly frameworks [11] and (iii) focusing on even the most novel processing techniques [12]. (ii) Lack of regulatory frameworks.…”